MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if MEDI4736 given in combination with
selumetinib can help to control advanced lung cancer.
The safety of this drug combination will also be studied.